ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jiuwei Cui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6496-7550, 0000-0002-5560-267X; OpenAlex author ID A5036233749, A5040858214. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 15

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 4

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Lingling Zhao · 1 shared paper, 2022 · strength 0.20
- Paper Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1016/j.hbpd.2021.08.012 ↗
Ri-Lan Bai · 1 shared paper, 2022 · strength 0.20
- Paper Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1016/j.hbpd.2021.08.012 ↗
Yaoxing Huang · 1 shared paper, 2021 · strength 0.15
- Paper Long intergenic non-protein coding RNA 960 regulates cancer cell viability, migration and invasion through modulating m… DOI 10.1080/21655979.2020.1868742 ↗
Chuntao Gao · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Jun Yao · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Jufeng Wang · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Liwei Wang · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Zhihua Li · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Tao Xia · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Yuhong Zhou · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Jiujie Cui · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Deliang Fu · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Shukui Qin · 1 shared paper, 2024 · strength 0.15
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4 ↗
Ji‐Fan Hu · 1 shared paper, 2015 · strength 0.05
- Paper Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer… DOI 10.1038/srep16975 ↗
Hongmei Yin · 1 shared paper, 2015 · strength 0.05
- Paper Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer… DOI 10.1038/srep16975 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.